N4 Pharma PLC Posting of Annual Report & Notice of AGM
29 Abril 2024 - 4:59AM
RNS Regulatory News
RNS Number : 4170M
N4 Pharma PLC
29 April 2024
N4 Pharma
plc
("N4
Pharma" or the "Company")
Posting of Annual Report
& Notice of AGM
N4 Pharma Plc (AIM: N4P), the
specialist pharmaceutical company developing Nuvec®, a novel
delivery system for cancer treatments and vaccines, announces that
its Annual Report and Accounts for the year ended 31 December 2023
and Notice of its Annual General Meeting ("AGM") have been posted
to shareholders.
The AGM will be held at 11:00am on
23 May 2024 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch
Street, London, EC3V 0HR.
The Group's Annual Report and
Accounts and the Notice of AGM are available on the Company's
website: https://www.n4pharma.com/
For
more information please contact:
|
N4
Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive
Director
|
investors.n4pharma.com
|
|
SP
Angel Corporate Finance
LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Caroline Rowe/Kasia
Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
|
Tel: +44(0)20 3470 0470
|
|
InvestorHub
Engage with us directly at N4 Pharma
Investor Hub
|
Sign up at investors.n4pharma.com
https://investors.n4pharma.com/link/4PKgJP
|
About N4 Pharma
N4 Pharma is a specialist
pharmaceutical company developing a novel delivery system for
oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to
partner with companies developing novel antigens in these fields to
use Nuvec® as the delivery vehicle for these antigens. As these
products progress through pre‐clinical and clinical programs, N4
Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the
market.
For further information on the
Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOASEASUUELSEIL
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
